AbbVie Inc (ABBV)

neg -0.54
Today's Range: 72.26 - 73.49 | ABBV Avg Daily Volume: 5,608,700
Last Update: 06/23/17 - 4:00 PM EDT
Volume: 7,027,733
YTD Performance: 16.86%
Open: $73.20
Previous Close: $73.18
52 Week Range: $55.06 - $73.67
Oustanding Shares: 1,591,540,513
Market Cap: 113,540,500,197
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 4 4 4
Moderate Buy 1 1 1 1
Hold 8 9 9 9
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.31 2.36 2.36 2.36
Latest Dividend: 0.64
Latest Dividend Yield: 3.59%
Dividend Ex-Date: 04/11/17
Price Earnings Ratio: 14.13
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
14.13 18.50 30.50
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
11.69% 21.18% 37.30%
Revenue 12.20 0.40 0.11
Net Income 15.70 0.40 0.13
EPS 16.00 0.40 0.12
Earnings for ABBV:
Revenue 25.64B
Average Earnings Estimates
Qtr (06/17) Qtr (09/17) FY (12/17) FY (12/18)
Average Estimate $1.40 $1.41 $5.52 $6.55
Number of Analysts 9 8 11 11
High Estimate $1.42 $1.46 $5.57 $7.00
Low Estimate $1.37 $1.37 $5.47 $6.26
Prior Year $1.26 $1.21 $4.82 $5.52
Growth Rate (Year over Year) 11.38% 16.32% 14.62% 18.59%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
How did Celgene, AbbVie and Gilead fare last quarter?
It doesn't look like Washington will be much help.

AbbVie Is Flexing Its Abs Real Money Pro($)

ABBV is now set up well for more upside.
The market is off to a decent start as investors try to digest scores of first-quarter earnings reports. Bristol-Myers Squibb (BMY) is just one of many large-cap drug and biotech companies reporting today. BMY shares are up as earnings and revenue easily surpassed estimates, powered by Opdivo growth. AbbVie (ABBV) also is up nicely. Its oncology product Imbruvica posted an almost 45% rise in year-over-year sales while Humira continues to see sales growth in the mid-teens
It is hard to keep up with the flurry of first-quarter earnings reports hitting the wires this morning. Here are a few that caught my eye today.
Biotech investors should keep a close eye on the progress in this huge potential market.

2 Biotech Pullback Targets Real Money Pro($)

Acadia and Neurocrine both have catalysts for growth; buy any weakness.
It's pretty normal to have profit-taking after such a strong first quarter.
Mar 10, 2017 | 6:51 AM EST
ABBV was placed on the Conviction Buy list, according to Goldman Sachs. $80 price target. Company is growing faster than its peers, but...
Icahn may have a tough time finding interest in this behemoth.

Columnist Conversations

we still like this trade but need some more time on it. SOLD WDC JUL 87.5 CALL AT 5.40 (in at 5.85) BOUG...
Impinj ( $PI) is still forming a bull flag. Holding up just fine, and 27% of float is short. This is a powe...
stellar numbers and the stock continues to attract buyers, it's now in the fat tail and this could go for a fe...
General Electric's outgoing CEO Jeff Immelt had some choice things to say at an event in NYC on Thursday ...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.